Wells Fargo’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.11M Sell
21,524
-39,548
-65% -$2.01M ﹤0.01% 3681
2025
Q4
$3.04M Buy
61,072
+19,306
+46% +$939K ﹤0.01% 3112
2025
Q3
$2M Sell
41,766
-28,470
-41% -$1.15M ﹤0.01% 3303
2025
Q2
$2.21M Buy
70,236
+5,546
+9% +$178K ﹤0.01% 3148
2025
Q1
$2.12M Buy
64,690
+1,453
+2% +$51.5K ﹤0.01% 3123
2024
Q4
$2.29M Buy
63,237
+7,961
+14% +$280K ﹤0.01% 3104
2024
Q3
$1.72M Buy
55,276
+31
+0.1% +$968 ﹤0.01% 3152
2024
Q2
$1.48M Buy
55,245
+6,444
+13% +$187K ﹤0.01% 3217
2024
Q1
$1.66M Buy
48,801
+2,327
+5% +$69.3K ﹤0.01% 3120
2023
Q4
$1.34M Sell
46,474
-549
-1% -$14.6K ﹤0.01% 3223
2023
Q3
$1.3M Sell
47,023
-14,771
-24% -$450K ﹤0.01% 3135
2023
Q2
$1.86M Buy
61,794
+10,071
+19% +$352K ﹤0.01% 2975
2023
Q1
$1.87M Buy
51,723
+10,090
+24% +$388K ﹤0.01% 2920
2022
Q4
$1.49M Sell
41,633
-7,825
-16% -$272K ﹤0.01% 2987
2022
Q3
$1.67M Sell
49,458
-3,806
-7% -$124K ﹤0.01% 2871
2022
Q2
$1.54M Sell
53,264
-53,174
-50% -$1.52M ﹤0.01% 2990
2022
Q1
$3.44M Sell
106,438
-12,328
-10% -$378K ﹤0.01% 2782
2021
Q4
$3.46M Sell
118,766
-23,641
-17% -$717K ﹤0.01% 2942
2021
Q3
$3.8M Buy
142,407
+17,296
+14% +$464K ﹤0.01% 3096
2021
Q2
$3.85M Sell
125,111
-87,065
-41% -$2.67M ﹤0.01% 3098
2021
Q1
$5.55M Buy
212,176
+78,857
+59% +$2.21M ﹤0.01% 2746
2020
Q4
$3.35M Sell
133,319
-7,248
-5% -$156K ﹤0.01% 3084
2020
Q3
$2.93M Buy
140,567
+11,916
+9% +$270K ﹤0.01% 3001
2020
Q2
$3.06M Buy
128,651
+9,622
+8% +$213K ﹤0.01% 2917
2020
Q1
$2.14M Sell
119,029
-39,725
-25% -$835K ﹤0.01% 2940
2019
Q4
$3.77M Sell
158,754
-47,897
-23% -$1.16M ﹤0.01% 2817
2019
Q3
$5.68M Sell
206,651
-71,326
-26% -$2.11M ﹤0.01% 2432
2019
Q2
$9.2M Sell
277,977
-92,033
-25% -$3.15M ﹤0.01% 2028
2019
Q1
$13M Sell
370,010
-240,625
-39% -$8.95M ﹤0.01% 1748
2018
Q4
$20.3M Sell
610,635
-183,048
-23% -$7.87M 0.01% 1365
2018
Q3
$40M Sell
793,683
-163,527
-17% -$8.08M 0.01% 1073
2018
Q2
$57.3M Buy
957,210
+61,100
+7% +$3.17M 0.02% 832
2018
Q1
$41M Buy
896,110
+140,688
+19% +$5.87M 0.01% 1011
2017
Q4
$30.1M Buy
755,422
+139,838
+23% +$5.53M 0.01% 1196
2017
Q3
$24.6M Sell
615,584
-45,691
-7% -$1.98M 0.01% 1281
2017
Q2
$28.5M Buy
661,275
+148,266
+29% +$5.28M 0.01% 1170
2017
Q1
$16.1M Buy
513,009
+4,241
+0.8% +$114K 0.01% 1526
2016
Q4
$12.8M Buy
508,768
+34,692
+7% +$775K ﹤0.01% 1676
2016
Q3
$11.7M Sell
474,076
-65,028
-12% -$1.47M ﹤0.01% 1656
2016
Q2
$11M Sell
539,104
-18,730
-3% -$332K ﹤0.01% 1757
2016
Q1
$8.51M Buy
557,834
+41,050
+8% +$536K ﹤0.01% 1933
2015
Q4
$6.95M Buy
516,784
+57,358
+12% +$887K ﹤0.01% 2113
2015
Q3
$6.45M Sell
459,426
-18,416
-4% -$342K ﹤0.01% 2132
2015
Q2
$8.11M Buy
477,842
+116,528
+32% +$1.66M ﹤0.01% 2068
2015
Q1
$4.37M Buy
361,314
+43,588
+14% +$412K ﹤0.01% 2473
2014
Q4
$2.64M Buy
317,726
+316,379
+23,488% +$2.66M ﹤0.01% 2809
2014
Q3
$12K Sell
1,347
-1,147
-46% -$10.4K ﹤0.01% 5512
2014
Q2
$27K Buy
+2,494
New +$22.2K ﹤0.01% 5235
2014
Q1
Sell
-31
Closed 6064
2013
Q4
$0 Buy
+31
New +$217 ﹤0.01% 5914

Other funds holding SUPN

Wells Fargo's SUPN Position: Q1 2026 in Review

Wells Fargo reduced its Supernus Pharmaceuticals (SUPN) stake by 65% in Q1 2026, selling an estimated $2.01M and leaving 21,524 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3681.

Wells Fargo first reported a position in SUPN in Q4 2013 and has held it in 49 quarters since. The position peaked at $57.3M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Wells Fargo held 21,524 shares of Supernus Pharmaceuticals worth $1.11M as of Q1 2026.
  • Wells Fargo sold 39,548 Supernus Pharmaceuticals shares in Q1 2026, an estimated $2.01M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3681 holding.
  • Wells Fargo first reported a position in Supernus Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
  • Wells Fargo's Supernus Pharmaceuticals position peaked at $57.3M in Q2 2018.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.